Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Acute Myeloid Leukemia
91%
Leukemia
34%
Venetoclax
30%
Ex Vivo
29%
Leukemia Cell
28%
Neoplasm
25%
Chronic Myelogenous Leukemia
24%
Disease
24%
Chronic Neutrophilic Leukemia
22%
Targeted Therapy
22%
Malignant Neoplasm
20%
Drug Response
18%
Atypical Chronic Myeloid Leukemia
18%
Receptor
17%
Tyrosine-Kinase Inhibitor
17%
Phosphotransferase Inhibitor
16%
Drug Sensitivity
16%
Phosphotransferase
15%
Protein Tyrosine Kinase
14%
Chronic Myelogenous Leukemia
12%
Acute Lymphoblastic Leukemia
12%
Myeloproliferative Neoplasm
12%
Dasatinib
11%
In Vitro
11%
Functional Genomics
10%
Signal Transduction
10%
RNA Interference
10%
Drug Resistance
10%
Hematologic Malignancy
9%
Clear Cell Renal Cell Carcinoma
8%
Rhabdomyosarcoma
8%
Programmed Cell Death
8%
Fibroblast Growth Factor 2
8%
Colony Stimulating Factor
8%
Xenograft
8%
Biological Marker
8%
Mitogen-Activated Protein Kinase
7%
Drug Screening
7%
Ponatinib
7%
Clinical Trial
7%
T Cell
6%
Ruxolitinib
6%
Cytokine
6%
Risk Stratification
6%
Quizartinib
6%
B-Cell Chronic Lymphocytic Leukemia
6%
Gene Expression
5%
Mononuclear Phagocyte
5%
Antineoplastic Activity
5%
Myeloproliferative Disorder
5%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Kinase
39%
Phosphotransferase
38%
Eicosanoid Receptor
25%
Receptor Tyrosine Kinase
21%
Genetics
18%
Proteomics
17%
Proteogenomics
17%
Drug Response
17%
Dasatinib
16%
Drug Sensitivity
15%
Small Molecule
14%
Tyrosine Kinase
13%
Tyrosine Kinase Inhibitor
11%
Cytokine
10%
Imatinib
9%
Functional Genomics
9%
Tyrosine
9%
Allele
9%
Drug Resistance
9%
Mouse
8%
Cancer Cell
8%
Tumor Progression
8%
Somatic Mutation
8%
P53
8%
RNA Interference
8%
Dimerization
7%
Hematopoiesis
7%
Point Mutation
6%
B Cell
6%
Kinome
6%
Monocyte
6%
Metabolomics
6%
Signal Transduction
6%
Cell Transformation
6%
Antineoplastic Activity
6%
Nilotinib
5%
Replication Timing
5%
BCL6
5%
Ubiquitin
5%
Mononuclear Phagocyte
5%
Colony-Stimulating Factor
5%
PTPN11
5%
Hematopoietic Cell
5%
Epidermal Growth Factor Receptor
5%
Genomics
5%
Transcriptomics
5%
Mitogen-Activated Protein Kinase
5%
Colony Formation
5%
Epigenetics
5%
Keyphrases
Acute Myeloid Leukemia
64%
Venetoclax
22%
Leukemia
17%
Targeted Therapy
15%
FMS-like Tyrosine Kinase 3 (FLT3)
15%
Bcl-2 Inhibitor
12%
Leukemia Patients
12%
Kinase Inhibitor
11%
Dasatinib
11%
BCR-ABL
10%
Drug Resistance
10%
In Cancer
10%
Myeloproliferative Neoplasms
9%
Hematological Malignancies
9%
Acquired Resistance
9%
Chronic Myeloid Leukemia
9%
Functional Genomics
9%
Therapeutic Target
8%
Inhibitor Screening
8%
Proteogenomics
8%
Chronic Neutrophilic Leukemia
8%
Drug Sensitivity
8%
Small Molecule Inhibitors
8%
Hematopoietic Stem Cells
8%
Functional Screening
8%
BCR-ABL Inhibitors
7%
Atypical Chronic Myeloid Leukemia
6%
Ponatinib
6%
Janus Kinase 2 (JAK2)
6%
CSF3R
6%
Myeloid Cell leukemia-1 (Mcl-1)
6%
AP24534
5%
RAS-MAPK Pathway
5%
Leukemia Microenvironment
5%
Kinome
5%
B Cell Receptor
5%
Colony-stimulating Factor 3 Receptor
5%
Tyrosine Kinase Inhibitor
5%
FLT3 mutation
5%
Acute Myeloid Leukemia Cells
5%
Apoptosis
5%